ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
122.40
+16.36 (+15.43%)
As of 3:49PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close106.04
Open113.00
Bid121.26 x 200
Ask121.38 x 200
Day's Range109.46 - 123.26
52 Week Range96.18 - 149.34
Volume5,769,819
Avg. Volume2,201,151
Market Cap27.217B
Beta1.07
PE Ratio (TTM)62.13
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Alexion Rockets As New Drug Proves Itself Against Blockbuster Soliris
    Investor's Business Daily2 hours ago

    Alexion Rockets As New Drug Proves Itself Against Blockbuster Soliris

    Alexion Pharmaceuticals reported adjusted profit of $1.68 per share and $930.9 million in sales for its first quarter.

  • Boston-bound Alexion gets $2.5B stock jolt as earnings, drug trial impress
    American City Business Journals4 hours ago

    Boston-bound Alexion gets $2.5B stock jolt as earnings, drug trial impress

    When the company moves into its new headquarters in the Seaport District this summer, it will become the state’s third most valuable drugmaker.

  • Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up
    Zacks5 hours ago

    Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up

    Alexion exceeds both earnings and sales expectations in the first quarter of 2018.The company also raised revenue and earnings guidance for 2018.

  • Barrons.com6 hours ago

    Drug Makers: A Dose of Robust Earnings

    With earnings season in full swing, pharma stocks got a boost today from AbbVie (ABBV), and Alexion Pharmaceuticals (ALXN), although Bristol-Myers Squibb (BMY) has given up its early gains. AbbVie said ...

  • Alexion (ALXN) Tops Q1 Earnings and Sales Beat Estimates
    Zacks8 hours ago

    Alexion (ALXN) Tops Q1 Earnings and Sales Beat Estimates

    Alexion surpassed earnings and revenue expectations in the first quarter of 2018.

  • Associated Press8 hours ago

    Alexion: 1Q Earnings Snapshot

    On a per-share basis, the New Haven, Connecticut-based company said it had net income of $1.11. Earnings, adjusted for one-time gains and costs, came to $1.68 per share. The results exceeded Wall Street ...

  • Investopediayesterday

    3 Charts That Suggest Biotech Stocks Are Headed Lower

    Rising levels of market volatility and subsequent selling pressure have started to take hold of the strongest performing market segments such as biotechnology. The sudden shift in sentiment now has some active traders talking about a long-term shift in trend. Traders who want to gain exposure to a broad range of biotechnology companies often look to exchange-traded products such as the iShares Nasdaq Biotechnology ETF.

  • Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX
    Zacksyesterday

    Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX

    Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.

  • The Wall Street Journalyesterday

    [$$] New Biotech Grabs Series A for Rare Disease Treatments

    Venture capitalists are betting $37 million that a trio of former Alexion Pharmaceuticals Inc. executives will lead startup Rallybio LLC to success in the rare-disease market.

  • Why Alexion Pharmaceuticals (ALXN) Might Surprise This Earnings Season
    Zacks2 days ago

    Why Alexion Pharmaceuticals (ALXN) Might Surprise This Earnings Season

    Alexion Pharmaceuticals (ALXN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

  • Is a Beat in Store for Alexion (ALXN) This Earnings Season?
    Zacks3 days ago

    Is a Beat in Store for Alexion (ALXN) This Earnings Season?

    Impressive sales of Alexion's blockbuster drug, Soliris might lead the company toward an earnings beat in Q1.

  • Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy?
    Zacks3 days ago

    Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy?

    Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy?

  • Alexion Slips On Reports Brazil Will Allow Copycats Of Blockbuster Soliris
    Investor's Business Daily6 days ago

    Alexion Slips On Reports Brazil Will Allow Copycats Of Blockbuster Soliris

    Alexion slid to a 10-month low Friday after reports emerged that Brazil's government will allow drugmakers to produce biologic copies of Alexion's blockbuster drug Soliris.

  • Benzinga6 days ago

    The Week Ahead In Biotech: PDUFA Dates, IPOs And More

    The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) is almost flat for the week after adding about 5 percent in the week ended April 13. Will the following catalytic events lead to a resumption ...

  • Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics
    Zacks8 days ago

    Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics

    The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.

  • Pharma M&A Active This Week: 4 Potential Buyout Targets
    Zacks13 days ago

    Pharma M&A Active This Week: 4 Potential Buyout Targets

    Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.

  • Alexion: Analysts Raise Their Target Prices
    Market Realist13 days ago

    Alexion: Analysts Raise Their Target Prices

    Alexion Pharmaceuticals (ALXN) is one of the leading biotechnology firms. Soliris is approved to treat aHUS (atypical hemolytic uremic syndrome) and PHN (paroxysmal nocturnal hemoglobinuria). Alexion’s latest acquisition of Wilson Therapeutics is a turnaround strategy that’s being implemented to restructure Alexion’s performance and investors’ sentiments in the market.

  • WTX101: A Superior Treatment for Wilson Disease
    Market Realist13 days ago

    WTX101: A Superior Treatment for Wilson Disease

    On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced the acquisition of Wilson Therapeutics, which is developing a “first-of-its-kind” treatment for Wilson disease. Currently, Wilson disease is treated with copper chelators, Penicillamine or Trientine, to remove copper from serum. The drug has the potential to become the standard of care for Wilson disease patients.

  • Wilson Disease: A Market Opportunity for Alexion
    Market Realist13 days ago

    Wilson Disease: A Market Opportunity for Alexion

    On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced the acquisition of Wilson Therapeutics. Wilson Therapeutics is developing a drug to treat Wilson disease. Wilson disease is a rare genetic disorder that’s potentially life-threatening.

  • Strategic Rationale behind Alexion’s Acquisition
    Market Realist13 days ago

    Strategic Rationale behind Alexion’s Acquisition

    Wilson Therapeutics is a biopharmaceutical company focused on developing rare disease therapies. The company is listed on the Nasdaq Stockholm Exchange and has a market capitalization of 6.5 billion Swedish kronor. Wilson Therapeutics is developing a novel therapy to treat Wilson disease, which is a rare genetic and chronic disorder characterized by an accumulation of copper in the brain, liver, and other vital organs.

  • Alexion to Acquire Wilson Therapeutics for $855 Million
    Market Realist13 days ago

    Alexion to Acquire Wilson Therapeutics for $855 Million

    On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio.

  • Alexion (ALXN) to Acquire Wilson Therapeutics for $855M
    Zacks14 days ago

    Alexion (ALXN) to Acquire Wilson Therapeutics for $855M

    Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.

  • How Alexion Could Diversify From Its Cash Cow To Battle Valeant, Teva
    Investor's Business Daily15 days ago

    How Alexion Could Diversify From Its Cash Cow To Battle Valeant, Teva

    Alexion Pharmaceuticals will snap up Wilson Therapeutics in a move that helps it diversify from its blockbuster franchise and compete with Valeant and Teva.

  • Jakafi Continues to Be Strong Growth Driver for Incyte in 2018
    Market Realist15 days ago

    Jakafi Continues to Be Strong Growth Driver for Incyte in 2018

    Incyte has projected Jakafi’s GAAP (generally accepted accounting principles) and non-GAAP revenues for full-year 2018 to fall in the range of $1.35 billion to $1.4 billion. This revenue performance could be driven by an anticipated rise in demand for the drug in existing rare blood cancer indications of myelofibrosis (or MF) and polycythemia vera (or PV) as well as from potential new indications such as graft versus host disease (or GVHD) and essential-thrombocythemia (or ET). Jakafi has been granted orphan drug designation in MF, PV, ET, GVHD, and acute lymphoblastic leukemia (ALL) indications.

  • NYSE trader: Here's why stocks are up and headline risk is down
    Yahoo Finance Video8 days ago

    NYSE trader: Here's why stocks are up and headline risk is down

    Keith Bliss of Cuttone and Company joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.